Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Apr;52(4):1545-8.
doi: 10.1128/AAC.01284-07. Epub 2008 Jan 28.

In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors

Delphine Desbois  1 , Bénédicte Roquebert, Gilles Peytavin, Florence Damond, Gilles Collin, Antoine Bénard, Pauline Campa, Sophie Matheron, Geneviève Chêne, Françoise Brun-Vézinet, Diane Descamps; French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2)
Affiliations

In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors

Delphine Desbois et al. Antimicrob Agents Chemother. 2008 Apr.

Abstract

We determine phenotypic susceptibility of human immunodeficiency virus type 2 (HIV-2) isolates to amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, saquinavir, and tipranavir. Saquinavir, lopinavir, and darunavir are potent against wild-type HIV-2 isolates and should be preferred as first-line options for HIV-2-infected patients. Other protease inhibitors are less active against HIV-2 than against HIV-1.

PubMed Disclaimer

References

    1. Adjé-Touré, C. A., R. Cheingsong, J. G. Garcia-Lerma, S. Eholie, M. Borget, J. Bouchez, R. A. Otten, C. Maurice, M. Sassan-Morokro, R. E. Ekpini, M. Nolan, T. Chorba, W. Heneine, and J. N. Nkengasong. 2003. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire. AIDS 17:S49-S54. - PubMed
    1. Colson, P., M. Henry, M. Tivoli, H. Gallais, J. A. Gastaut, J. Moreau, and C. Tamalet. 2003. Polymorphism and drug-selected mutations in the reverse transcriptase of HIV-2 from patients living in southern France, abstr. 145. XII Int. HIV Drug Resist. Workshop: Basic Princ. Clin. Implications, Los Cabos, Mexico.
    1. Damond, F., F. Brun-Vezinet, S. Matheron, G. Peytavin, P. Campa, S. Pueyo, F. Mammano, S. Lastere, I. Farfara, F. Simon, G. Chene, and D. Descamps. 2005. Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors. J. Clin. Microbiol. 43:484-487. - PMC - PubMed
    1. Damond, F., G. Collin, S. Matheron, G. Peytavin, P. Campa, S. Delarue, A. Taieb, A. Benard, G. Chene, F. Brun-Vezinet, and D. Descamps. 2005. In vitro phenotypic susceptibility to nucleoside reverse transcriptase inhibitors of HIV-2 isolates with the Q151M mutation in the reverse transcriptase gene. Antivir. Ther. 10:861-865. (Letter.) - PubMed
    1. De Wit, M., I. Keuleers, E. Gustin, I. Dierynck, S. Hallenberger, and K. Hertogs. 2007. Binding kinetics of PI to wild type and multi drug resistant HIV-1 proteases: a mechanistic study of the genetic barrier to resistance to darunavir, abstr. 605. XIV Conf. Retroviruses Opportunistic Infect., Los Angeles, CA, 25 to 28 February 2007.

Publication types

LinkOut - more resources